Clinicaltrials.gov identifier:
NCT03462342 (https://clinicaltrials.gov/show/NCT03462342)
Treatment
Recurrent ovarian cancer
Study Contact Information:
For additional information, please contact: Diego Rodriguez by phone 1-215-614-0234 or by email.
This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.
This is an open-label, non-randomized, phase 2 study.
Study Group A
Participants assigned to this group have recurrent high grade serous ovarian, primary peritoneal or fallopian tube cancer for which standard curative treatments are no longer effective. These participants will receive:
Study Group B
Participants assigned to this group have recurrent high grade serous ovarian, primary peritoneal or fallopian tube cancer for which standard curative treatments are no longer effective. Participants must have 3 or fewer courses of chemotherapy since developing platinum-resistance. These participants will receive:
For Study Group C
Participants assigned to this group have recurrent high grade serous ovarian, primary peritoneal or fallopian tube cancer for which standard curative treatments are no longer effective. Participants in this group must have received prior treatment with a PARP inhibitor, must have platinum sensitive disease, and must have either an inherited BRCA mutation or tumor mutation in BRCA1, BRCA2 or another "HRD gene" (for example PALB2) or biomarker testing that show that their tumor is HRD-positive. These participants will receive:
For Study Group D1
Participants in this group may have any type of non-mucinous epithelial ovarian cancer (including clear cell or endometrioid types). Participants may be either platinum-sensitive or platinum-resistant. These participants will receive:
For Study Group D2
Participants assigned to this group have recurrent high grade serous ovarian, primary peritoneal or fallopian tube cancer for which standard curative treatments are no longer effective. Participants in this group must have received prior treatment with a PARP inhibitor, must have platinum sensitive disease, and must have either an inherited BRCA mutation or tumor mutation in BRCA1, BRCA2 or another "HRD gene" (for example PALB2) or biomarker testing that show that their tumor is HRD-positive. These participants will receive:
Maryland
Baltimore, MD
Johns Hopkins University School of Medicine
Contact Mary Kate Jones by email at: [email protected]
Massachusetts
Boston, MA
Dana-Farber Cancer Institute
Contact: Kim MacNeill by email at: [email protected]
Pennsylvania
Philadelphia, PA
Hospital of the University of Pennsylvania
Contact: Diego Rodriguez by phone: 215-614-0234 or by [email protected]
Contact: Fiona Simpkins, MD by phone 215-662-7336 or by email: [email protected]
People who belong to any of these groups may participate:
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.